Changes of RAPD profile of Trypanosoma cruzi II with Canova and Benznidazole

Homeopathy

Volumn 97, Issue 2, 2008, Pages 59-64

  Aleixo, Denise Lessa ^a   Ferraz, Fabiana Nabarro ^a   de Melo, Carolina Sundin ^a   Gomes, Mônica Lúcia ^a   Toledo, Max Jean ^a   Kaneshima, Edílson Noboyoshi ^a   Bersani Amado, Ciomar Aparecida ^a   Araújo, Silvana Marques ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Benznidazole; Canova medication; Homeopathy; RAPD; T. cruzi II; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; CANOVA; DNA; HOMEOPATHIC AGENT; POLYACRYLAMIDE GEL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DNA EXTRACTION; DRUG MECHANISM; GENE AMPLIFICATION; MALE; MOUSE; NONHUMAN; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

ANIMALS; CHAGAS DISEASE; CROTALID VENOMS; DNA, PROTOZOAN; MATERIA MEDICA; MICE; NITROIMIDAZOLES; PLANT EXTRACTS; RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 42949136962     PISSN: 14754916     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.homp.2008.02.003     Document Type: Article

References (29)

1. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vetorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 98 5 (2003) 577-591
2. OPS (Organización Panamericana de la Salud). XIII Reunion de la comisión Intergubernamental para la eliminación de Triatoma infestans y la interrupción de la tripanosomiasis Americana por transfusion. 2004, pp 29-31.
3. Suasnáber D., Arias E., and Streiger M. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop São Paulo 42 (2000) 99-109
4. Laguens R.P., Cabeza Meckert P.M., and Vigliano C.A. Pathogenesis of human chronic chagasic myocarditis. Medicina (B Aires) 59 2 (1999) 63-68
5. Higuchi M.L., Gutierrez P.S., and Aiello V.D. Immunohistochemical characterization of infiltrating cells in human chronic chagasic myocarditis: comparison with myocardial rejection process. Virchows Arch A Pathol Anat Histol 423 (1993) 157-160
6. Reyes P.A., and Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev 4 (2005) [Art. No.: CD004102]
7. Fabbro D.L., Streiger M.L., Arias E.D., Bizai M.L., Del Barco M., and Amicone N.A. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 40 1 (2007 Jan-Feb) 1-10
8. Toledo M.J.O., Bahia M.T., Veloso V.M., et al. Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes. J Antim Chemot 53 6 (2004) 1045-1053
9. Pupulin ART, Neto IR, Gabriel M. Avaliação dos efeitos do medicamento Canova sobre a infecção experimental de camundongos pelo Trypanosoma cruzi. In: Anais da XX Reunião Anual de Pesquisa Aplicada em doença de Chagas e VIII Reunião Anual de Pesquisa Aplicada de Leishmaniose, Uberaba, 2004.
10. Ribeiro Filho A. Repertório de Homeopatia Ed Organon, 1a Edição, p 1900.
11. Pereira W.K.V., Lonardoni M.V.C., Grespan R., Caparroz-Assef S.M., Cuman R.K.N., and Bersani-Amado C.A. Immunomodulatory effect of Canova medication on experimental Leishmania amazonensis infection. J Infect 51 (2005) 157-164
12. Sasaki M.G.M., Mariano F.C., Gurgel L.P., and Probst S. Estudo clínico randomizado placebo controlado para avaliar a eficácia e segurança do Método Canova na terapêutica de pacientes portadores de HIV/Aids em uso de anti-retrovirais. Braz J Infect Dis 5 1 (2001) 58
13. Seligmann I.C., Lima P.D.L., Cardoso P.C.S., et al. The anticancer homeophathic composite "Canova Method" is not genotoxic for human lymphocytes in vitro. Genet Mol Res 2 2 (2003) 223-228
14. Piemonte M.R., and Buchi D.F. Analysis of IL-2, IFN-γ and TNF-α production, α5β1 integrins and actin filaments distribution in peritoneal mouse macrophages treated with homeopathic medicament. J Submicrosc Cytol Pathol 34 3 (2002) 255-263
15. Bellavite P., Ortolani R., Pontarollo F., Piasere V., Benato G., and Conforti A. Immunology and homeopathy. Clinical studies - part 1. eCAM (2006) 1-9
16. Brisse S., Verhoef J., and Tibayrenc M. Characterisation of large and small subunit rRNA and mini-exon genes further supports the distinction of six Trypanosoma cruzi lineages. Int J Parasitol 31 11 (2001) 1218-1226
17. Walsh J., and McClelland M. Genomic fingerprinting using arbitrary primed PCR and a matrix of pairwise combination of primers. Nucleic Acids Res 18 (1990) 7213-7218
18. Willians J., Kubelik A.R., and Livak K.J. DNA polymorphisms amplified by arbitrary primers are useful as genetic markers. Nucleic Acids Res 18 (1990) 6531-6535
19. Pereira da Silva L.H., and Nussensweig V. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. Folia Clin Biol (Sao Paulo) 20 30 (1953) 191-208
20. Araújo S.M., and Chiari E. Caracterização biológica de clones das cepas Y, CL e MR de Trypanosoma cruzi em camundongos C3H isogênicos. Mem Inst Oswaldo Cruz 83 (1988) 175-181
21. Macedo A.M., Martins M.S., Chiari E., and Pena S.D.J. DNA fingerprinting of Trypanosoma cruzi: a new tool for characterization of strains and clones. Mol Biochem Parasitol 55 (1992) 147-154
22. Gomes M.L., Macedo A.M., Pena S.D.J., and Chiari E. Genetic relationship between Trypanosoma cruzi strains isolated from chronic chagasic patients in southern Brazil as revealed by RAPD and SSR-PCR analysis. Acta Trop 69 (1998) 99-109
23. D`Ávila D.A., Gontijo E.D., Lages-Silva E., Meira W.S.F., Chiari E., and Galvão L.M.C. Random amplified polymorphic DNA profiles of Trypanosoma cruzi isolates from chagasic patients with different clinical forms. Parasitol Res 98 (2006) 455-461
24. Godoy L.C., Cardozo R.M., and Moraes G.V. Avaliação de diversidade genética em subspécies e cruzamento de avestruzes (Struthio camelus) com o uso de maracadores RAPD. Acta Sci 27 2 (2005) 199-206
25. Pupulin ART, Araújo SM, Bersani-Amado CAB. Efeito do medicamento Canova sobre o nível de TNF-alfa no plasma de camundongos infectados pelo Trypanosoma cruzi. In: Anais da XXI Reunião Anual de Pesquisa Aplicada em Doença de Chagas e Leishmaniose: XXI Reunião Anual de Pesquisa Aplicada em Doença de Chagas e Leishmaniose, Uberaba, 2005.
26. Murta S.M.F., Ropert C., Alves R.O., Gazzinelli R.T., and Romanha A.J. In-vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a derived drug-resistant Trypanosoma cruzi population. Parasite Immunol 21 10 (1999) 535-544
27. Romanha A.J., Alves R.O., Murta S.M., Silva J.S., Ropert C., and Gazzinelli R.T. Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. J Infect Dis 186 6 (2002) 823-828
28. Lopes L., Godoy L.M.F., Oliveira C.C., Gabardo J., Schadeck R.J.G., and Buchi D.F. Phagocytosis, endosomal/lysosomal system and other cellular aspects of macrophage activation by Canova medication. Micron 37 (2006) 277-287
29. Oliveira C.C., Oliveira S.M., Godoy L.M.F., Gabardo J., and Buchi D.F. Canova, a Brazilian medical formulation, alters oxidative metabolism of mice macrophages. J Infect 52 (2006) 420-432